Pieris Corp (PVLA) - Long-Term Debt to Capital Coefficient
This chart of current Pieris Pharmaceuticals (PVLA) quotes on the GURU.Markets platform, where the indicator stands at 0.10, depends on the transition of production to eco-friendly closed-loop cycles. The business, which develops immune drugs, is currently undergoing a non-profitable restructuring under a strict R&D spending limit. Meanwhile, assets remain crisis-resistant, as the success of molecules is independent of economic conditions.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_PVLA_-_Pieris-Pharmaceuticals_-_Long-Term-Debt-to-Capital "PVLA: Pieris Pharmaceuticals, Inc. Long-Term Debt to Capital 07/04/2022 - 10/31/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Pieris Pharmaceuticals (PVLA)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Pieris Pharmaceuticals|PVLA - Long-Term Debt to Capital|Short-Term Debt to Capital pieris.com|PVLA - Company Total Debt|Debt to Net Assets Ratio Pieris Pharmaceuticals, Inc.|PVLA - Company Long-Term Debts|Short-Term Debt Volume Pieris Pharmaceuticals|Quick Liquidity Indicator pieris.com
- net income and valuation ratios data:
General company analysis:Pieris Pharma - PVLA
The success of Pieris Pharmaceuticals (PVLA) depends on clinical trials and strategic alliances, rendering the company independent of economic cycles. The long-term debt-to-equity ratio measures financial leverage, where the market value of shares constantly adjusts the denominator, allowing investors to determine the balance between default risks and business growth potential through the assessment of long-term debt to equity.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient KNSA (Kiniksa Pharmaceuticals, Ltd.)|Grifols Group (GRFS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Adaptive Biotechnologies Inc.|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com|Long-Term Debt to Equity Ratio BCRX (BioCryst Pharmaceuticals)|VERA (Vera Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital DNTH (Dianthus Pharma)|Ratio of Long-Term Indebtedness to Capital Pharvaris Pharma (PHVS)|ABCL - Long-Term Debt to Equity|tourmalinebio.com (TRML) - Long-Term Debt to Equity Ratio|Precigen (PGEN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|Long-Term Debt to Equity Ratio NKTR|Long-Term Debt to Capital Upstream Pharma|Long-Term Debt to Equity Zenas Biopharma Inc (ZBIO)|immunome.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital GOSS (Gossamer Bio)|KalVista Pharma (KALV) - Long-Term Liabilities to Capital|SEPN - Long-Term Debt to Equity|Long-Term Liabilities to Equity SVRA|RIGL: Long-Term Debt to Capital|ANAB - Ratio of Long-Term Indebtedness to Capital|ATXS (Astria Therapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital enGene Holdings Inc ENGN|Long-Term Debt to Equity RAPT Therapeutics, Inc. (RAPT)|JBIO (aerovatetx.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ACRS (Aclaris Therapeutics)|Ratio of Long-Term Indebtedness to Capital kyvernatx.com (KYTX)|TLSA - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Cabaletta Bio Inc. CABA|VTYX (Ventyx Bio) - Long-Term Debt to Equity Ratio|Theratechnologies, Inc - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Avalo Therapeutics, Inc|eledon.com - Long-Term Liabilities to Equity|Long-Term Debt to Capital AGEN|CLYM (Climb Bio Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ZURA (Zura Bio Limited)|Long-Term Debt to Capital aTyr Pharmaceuticals ATYR|ADAG - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient IMA (ImageneBio Inc)|shattucklabs.com (STTK) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Equillium|CNTB (Connect Biopharma Holdings) - Long-Term Debt to Capital|Long-Term Debt to Capital Immunic Inc|Long-Term Debt to Capital ATRA|Long-Term Debt to Equity Ratio inflarx.de IFRX|Long-Term Debt to Capital XFOR (X4 Pharmaceuticals, Inc.)|Adicet Bio Inc. (ACET) - Long-Term Liabilities to Capital|CELU: Long-Term Debt to Equity Ratio|INMB - Long-Term Debt to Capital|BRNS (Barinthus Biotherapeutics) - Long-Term Debt to Equity Ratio|KZR: Long-Term Loans to Capital Ratio|SABS (SAB Biotherapeutics, Inc.) - Long-Term Debt to Capital|Akari Therapeutics PLC (AKTX) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital ENLV|Long-Term Debt to Equity Ratio q32bio.com QTTB|Long-Term Debt to Capital GOVX (GeoVax Labs, Inc.)|Long-Term Debt to Capital edesabiotech.com EDSA|IBIO - Long-Term Debt to Equity|CARM: Long-Term Debt to Equity|XTL Biopharmaceuticals, Ltd. (XTLB) - Long-Term Debt to Equity|BOLT - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity HCW Biologics, Inc.|Aptevo - Long-Term Liabilities to Equity|Long-Term Debt to Equity Ratio AIM (AIM ImmunoTech)|Long-Term Debt to Equity ADTX (aditxt.com)|Long-Term Debt to Equity GRI Bio Corp GRI|XORTX Corp - Long-Term Debt to Equity|Vyome Holdings Inc - Long-Term Debt to Capital|REVB - Long-Term Debt to Capital|Indaptus Therapeutics, Inc. (INDP) - Long-Term Debt to Equity|Long-Term Liabilities to Equity SCNI (Scinai Immunotherapeutics Ltd)|CALI (CalciMedica Inc) - Long-Term Debt to Capital|AFMD: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ALLK|Long-Term Debt to Capital hookipapharma.com (HOOK)|Long-Term Debt to Equity IGM Biosciences IGMS|Long-Term Debt to Capital Coefficient ITOS|OCEA - Long-Term Debt to Equity|TC BioPharm Ltd (TCBP) - Long-Term Debt to Equity Ratio|THRD: Long-Term Debt to Capital